Gregg Gilbert
Stock Analyst at Truist Securities
(2.25)
# 2,549
Out of 5,182 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $18.34 | -7.31% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $32.78 | +12.87% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $57.78 | +45.38% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $868.27 | -39.53% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $5.22 | +149.04% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $12.48 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $110.23 | -15.63% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $23.42 | +104.95% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.84 | +1,313.04% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.61 | +24,490.16% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $11.49 | +578.85% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $117.87 | -33.83% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $31.26 | -42.42% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $241.79 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $201.22 | -13.03% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $197.38 | -66.56% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $18.34
Upside: -7.31%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $32.78
Upside: +12.87%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $57.78
Upside: +45.38%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $868.27
Upside: -39.53%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $5.22
Upside: +149.04%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $12.48
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $110.23
Upside: -15.63%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $23.42
Upside: +104.95%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.84
Upside: +1,313.04%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.61
Upside: +24,490.16%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $11.49
Upside: +578.85%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $117.87
Upside: -33.83%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $31.26
Upside: -42.42%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $241.79
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $201.22
Upside: -13.03%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $197.38
Upside: -66.56%